<DOC>
	<DOCNO>NCT00292799</DOCNO>
	<brief_summary>This study aim investigate role weight reduction agent , Orlistat compare Metformin management woman obese ovulate difficulty conceiving . Patients receive either one medication monitor regular interval hormone blood test ultrasound scan order study effect medication reproductive function . Patients receive medication three month study end patient becomes pregnant . The study also aim investigate dose metformin use consensus date regard optimum dosage drug</brief_summary>
	<brief_title>An RCT Metformin Vs Orlistat Obese Anovulatory Women</brief_title>
	<detailed_description>We aim recruit 40 patient suffer anovulatory obesity BMI 30 . Patients include ethnic group . Patients baseline history , clinical examination , hormonal profile ( FSH/LH , fast Insulin/glucose ratio , androgen profile , day 21 serum progesterone , serum leptin ghrelin level ) ultrasound examination ( ovarian volume antral follicle count ) , include Doppler blood flow study ( ovarian stromal velocity , PI , RI , SD ratio power Doppler ) Participants randomise receive either metformin orlistat . Patients receive orlistat receive standard dose drug recommend BNF . Metformin give incremental dose start 1000mg per day increase 4 weekly interval 2000mg/d , depend occurrence gastrointestinal intolerance . The endocrinological ultrasound investigation repeat 4 weekly interval . Both group give standard exercise diet program conjunction medical treatment . The clinical endpoint achievement conception , Body Mass Index less 30 , completion 3-month course treatment . Study design : A randomised control open label clinical trial . Participants randomise use computer generate randomisation program available pharmacy Jessop Wing , either one two arm : metformin orlistat . The randomisation stratify order achieve homogenous distribution PCOS non-PCOS patient arm study .</detailed_description>
	<mesh_term>Anovulation</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>1 . In childbearing period 2 . Obese body mass index 30 . 3 . Are anovulatory show day 21serum progesterone . 4 . Polycystic ovarian syndrome diagnose accord least two follow three feature present , exclusion aetiology ( Azziz , 2004 ) : ( ) Oligo anovulation , ( ii ) Clinical and/or biochemical hyperandrogenism ( iii ) Polycystic ovary . 1 . BMI less 30 2 . Patients request treatment symptom 3 . Patients contraindication medication : renal hepatic impairment , malabsorption syndrome , cholestasis 4 . Diabetic patient 5 . Pregnancy 6 . Breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>metformin</keyword>
	<keyword>orlistat</keyword>
</DOC>